EGFR and non-small cell lung carcinoma: In conclusion, according to the recommended WTP threshold (3×per-capita GDP) of cost-effectiveness guidelines from WHO, maintenance gefitinib therapy after the standard chemotherapy of four chemotherapeutic cycles in locally advanced/metastatic NSCLC patients with unknown EGFR mutations is likely to be not cost-effective for Chinese mainland, from the Chinese health care system perspective.